Aktis Oncology, Inc. (Ticker: AKTS US) is a U.S. clinical-stage biotechnology company developing a proprietary miniprotein radioconjugate platform for solid tumors. The company engineers proteins designed to deliver alpha-emitting Actinium-225 to validated targets, optimizing for deep tumor penetration and rapid systemic clearance to minimize toxicity. Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4 and is currently in a Phase 1b trial.

Aktis plans to list on the NASDAQ on January 9, 2026. Offering 17.7 million shares at $16.00–$18.00, the IPO aims to raise approximately $300 million at a ~$900 million valuation after upsizing the offer follwoing a $100 million cornerstone investment by Eli Lilly.
J.P. Morgan, BofA Securities, Leerink Partners, and TD Cowen are the underwriters. Proceeds will reportedly fund the lead program's clinical advancement and the progression of a second candidate targeting B7-H3 into trials.